Indication
Primary Myelofibrosis (PMF)
8 clinical trials
8 products
Product
BomedemstatClinical trial
A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With MyelofibrosisStatus: Completed, Estimated PCD: 2022-03-08
Product
RuxolitinibClinical trial
Phase 1b Study of PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Treated With RuxolitinibStatus: Terminated, Estimated PCD: 2022-10-19
Product
PU-H71Clinical trial
A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Status: Completed, Estimated PCD: 2017-07-18
Product
MMBClinical trial
A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor TreatmentStatus: Recruiting, Estimated PCD: 2023-12-31
Product
Best Available TherapyProduct
KRT-232Clinical trial
A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With RuxolitinibStatus: Completed, Estimated PCD: 2016-07-28
Product
MomelotinibClinical trial
Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)Status: Active (not recruiting), Estimated PCD: 2026-12-31
Product
JaktinibClinical trial
Jaktinib in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With RuxolitinibStatus: Completed, Estimated PCD: 2022-08-03